Following an increase in plasma supplied, nearly double, the Oxford Centre was able to transfer several patients from commercial to NHS concentrate. Read more about Following an increase in plasma supplied, nearly double, the Oxford Centre was able to transfer several patients from commercial to NHS concentrate.
By 1976, 42.6% of the material used at Oxford Haemophilia Centre was NHS Factor 8 concentrate, just 1.54% was cryoprecipitate, and the rest was commercial concentrate (Hyland & Immuno). Read more about By 1976, 42.6% of the material used at Oxford Haemophilia Centre was NHS Factor 8 concentrate, just 1.54% was cryoprecipitate, and the rest was commercial concentrate (Hyland & Immuno).
In 1977, Dr Bidwell said Factor 9 requirements had increased substantially. It did not allow for prophylactic treatment except for occasional short periods. But prophylaxis for severely affected patients was allowed where no substantial increase in usage occurred. Read more about In 1977, Dr Bidwell said Factor 9 requirements had increased substantially. It did not allow for prophylactic treatment except for occasional short periods. But prophylaxis for severely affected patients was allowed where no substantial increase in usage occurred.
By 1975 there was only about 25% of Haemophilia A patients using home therapy. Read more about By 1975 there was only about 25% of Haemophilia A patients using home therapy.
Between 1969 to 1974, cryoprecipitate use at the Oxford Haemophilia Centre dropped from 21.99% to 3.86% of total Factor 8 material used, while the use of NHS concentrate rose from 45.93% to 60.89% of the total. Read more about Between 1969 to 1974, cryoprecipitate use at the Oxford Haemophilia Centre dropped from 21.99% to 3.86% of total Factor 8 material used, while the use of NHS concentrate rose from 45.93% to 60.89% of the total.
Due to the co-location and cooperation of the PFL and Oxford Haemophilia Centre, it made the switch from cryoprecipitate to factor concentrates relatively early. Read more about Due to the co-location and cooperation of the PFL and Oxford Haemophilia Centre, it made the switch from cryoprecipitate to factor concentrates relatively early.
Dr Biggs served as director until 1977 when she was succeeded by Dr Rizza. Read more about Dr Biggs served as director until 1977 when she was succeeded by Dr Rizza.
Dr Biggs served as director of the Oxford Reference Centre until 1977 when she was succeeded by Dr Rizza. Read more about Dr Biggs served as director of the Oxford Reference Centre until 1977 when she was succeeded by Dr Rizza.
Dr Craske published an article titled 'An outbreak of hepatitis associated with intravenous injection of Factor VIII concentrate' in The Lancet Read more about Dr Craske published an article titled 'An outbreak of hepatitis associated with intravenous injection of Factor VIII concentrate' in The Lancet
Dr Kernoff agreed with Dr Dormany that factor concentrates exposed recipients to a greater risk of infection because of the large sizes of the pools from which they were made. Read more about Dr Kernoff agreed with Dr Dormany that factor concentrates exposed recipients to a greater risk of infection because of the large sizes of the pools from which they were made.